{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,17]],"date-time":"2026-04-17T04:30:30Z","timestamp":1776400230242,"version":"3.51.2"},"reference-count":38,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,6,1]],"date-time":"2024-06-01T00:00:00Z","timestamp":1717200000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,12,22]],"date-time":"2024-12-22T00:00:00Z","timestamp":1734825600000},"content-version":"am","delay-in-days":204,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Respiratory Medicine and Research"],"published-print":{"date-parts":[[2024,6]]},"DOI":"10.1016\/j.resmer.2023.101069","type":"journal-article","created":{"date-parts":[[2023,12,1]],"date-time":"2023-12-01T00:12:10Z","timestamp":1701389530000},"page":"101069","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"special_numbering":"C","title":["Cancer-associated thrombosis: How many patients seen in clinical practice would be eligible for a direct oral anticoagulant randomized controlled trial?"],"prefix":"10.1016","volume":"85","author":[{"given":"Bastien","family":"Petit","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Simon","family":"Soudet","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8020-9215","authenticated-orcid":false,"given":"G\u00e9raldine","family":"Poenou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Emma","family":"Zarrat","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sandrine","family":"Accassat","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ludovic","family":"Plaisance","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"H\u00e9l\u00e8ne","family":"Helfer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Valentine","family":"Mismetti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Claire Le","family":"Hello","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marie-Antoinette","family":"Sevestre","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Isabelle","family":"Mah\u00e9","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8214-3010","authenticated-orcid":false,"given":"Laurent","family":"Bertoletti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.resmer.2023.101069_bib0001","first-page":"57\u201165","article-title":"Epidemiology of first and recurrent venous thromboembolism in patients with active cancer","volume":"26","author":"Cohen","year":"2017","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.resmer.2023.101069_bib0002","doi-asserted-by":"crossref","first-page":"380","DOI":"10.3390\/cancers10100380","article-title":"Cancer-associated thrombosis: an overview of mechanisms, risk factors, and treatment","volume":"10","author":"Abdol Razak","year":"2018","journal-title":"Cancers"},{"key":"10.1016\/j.resmer.2023.101069_bib0003","doi-asserted-by":"crossref","first-page":"1712\u201123","DOI":"10.1182\/blood-2013-04-460121","article-title":"Epidemiology of cancer-associated venous thrombosis","volume":"122","author":"Timp","year":"2013","journal-title":"Blood"},{"key":"10.1016\/j.resmer.2023.101069_bib0004","doi-asserted-by":"crossref","first-page":"654\u20116","DOI":"10.1200\/JCO.2014.59.7351","article-title":"Venous thromboembolism prophylaxis and treatment in patients with cancer: American society of clinical oncology clinical practice guideline update 2014","volume":"33","author":"Lyman","year":"2015","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"key":"10.1016\/j.resmer.2023.101069_bib0005","first-page":"1128\u201136","article-title":"Direct oral anticoagulants for the treatment of acute venous thromboembolism associated with cancer: a systematic review and meta-analysis","volume":"120","author":"Giustozzi","year":"2020","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.resmer.2023.101069_bib0006","doi-asserted-by":"crossref","first-page":"927\u201174","DOI":"10.1182\/bloodadvances.2020003442","article-title":"American Society of Hematology 2021 guidelines for management of venous thromboembolism: prevention and treatment in patients with cancer","volume":"5","author":"Lyman","year":"2021","journal-title":"Blood Adv"},{"key":"10.1016\/j.resmer.2023.101069_bib0007","first-page":"427\u201137","article-title":"Treatment of cancer associated thrombosis. 2019 update of the French guidelines","volume":"38","author":"Mah\u00e9","year":"2021","journal-title":"Rev Mal Respir"},{"key":"10.1016\/j.resmer.2023.101069_bib0008","first-page":"1289\u2011303","article-title":"NCCN guidelines insights: cancer-associated venous thromboembolic disease, version 2.2018","volume":"16","author":"Streiff","year":"2018","journal-title":"J Natl Compr Cancer Netw JNCCN"},{"key":"10.1016\/j.resmer.2023.101069_bib0009","doi-asserted-by":"crossref","first-page":"1891\u20114","DOI":"10.1111\/jth.14219","article-title":"Role of direct oral anticoagulants in the treatment of cancer-associated venous thromboembolism: guidance from the SSC of the ISTH","volume":"16","author":"Khorana","year":"2018","journal-title":"J Thromb Haemost JTH"},{"key":"10.1016\/j.resmer.2023.101069_bib0010","doi-asserted-by":"crossref","first-page":"e566\u201181","DOI":"10.1016\/S1470-2045(19)30336-5","article-title":"2019 international clinical practice guidelines for the treatment and prophylaxis of venous thromboembolism in patients with cancer","volume":"20","author":"Farge","year":"2019","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.resmer.2023.101069_bib0011","doi-asserted-by":"crossref","first-page":"496\u2011520","DOI":"10.1200\/JCO.19.01461","article-title":"Venous thromboembolism prophylaxis and treatment in patients with cancer: ASCO clinical practice guideline update","volume":"38","author":"Key","year":"2020","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.resmer.2023.101069_bib0012","doi-asserted-by":"crossref","first-page":"615\u201124","DOI":"10.1056\/NEJMoa1711948","article-title":"Edoxaban for the treatment of cancer-associated venous thromboembolism","volume":"378","author":"Raskob","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1016\/j.resmer.2023.101069_bib0013","doi-asserted-by":"crossref","DOI":"10.1056\/NEJMoa1915103","article-title":"Apixaban for the treatment of venous thromboembolism associated with cancer","author":"Agnelli","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.resmer.2023.101069_bib0014","doi-asserted-by":"crossref","first-page":"684\u201191","DOI":"10.1002\/cpt.781","article-title":"Real-life use of anticoagulants in venous thromboembolism with a focus on patients with exclusion criteria for direct oral anticoagulants","volume":"103","author":"Moustafa","year":"2018","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.resmer.2023.101069_bib0015","doi-asserted-by":"crossref","first-page":"315\u201152","DOI":"10.1016\/j.chest.2015.11.026","article-title":"Antithrombotic therapy for VTE disease","volume":"149","author":"Kearon","year":"2016","journal-title":"Chest"},{"key":"10.1016\/j.resmer.2023.101069_bib0016","doi-asserted-by":"crossref","first-page":"692\u20114","DOI":"10.1111\/j.1538-7836.2005.01204.x","article-title":"Scientific the SOCOAOT, thrombosis SC of the ISO, haemostasis. Definition of major bleeding in clinical investigations of antihemostatic medicinal products in non-surgical patients","volume":"3","author":"Schulman","year":"2005","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.resmer.2023.101069_bib0017","doi-asserted-by":"crossref","first-page":"2119\u201126","DOI":"10.1111\/jth.13140","article-title":"Anticoagulation the S on C of. Definition of clinically relevant non-major bleeding in studies of anticoagulants in atrial fibrillation and venous thromboembolic disease in non-surgical patients: communication from the SSC of the ISTH","volume":"13","author":"Kaatz","year":"2015","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.resmer.2023.101069_bib0018","unstructured":"https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/eliquis."},{"key":"10.1016\/j.resmer.2023.101069_bib0019","unstructured":"https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/xarelto."},{"key":"10.1016\/j.resmer.2023.101069_bib0020","doi-asserted-by":"crossref","first-page":"337\u201147","DOI":"10.1016\/j.amjmed.2016.10.017","article-title":"The clinical course of venous thromboembolism may differ according to cancer site","volume":"130","author":"Mah\u00e9","year":"2017","journal-title":"Am J Med"},{"key":"10.1016\/j.resmer.2023.101069_bib0021","doi-asserted-by":"crossref","first-page":"907\u201116","DOI":"10.1111\/jth.13664","article-title":"Long-term outcomes of cancer-related isolated distal deep vein thrombosis: the OPTIMEV study","volume":"15","author":"Galanaud","year":"2017","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.resmer.2023.101069_bib0022","doi-asserted-by":"crossref","first-page":"1713\u201120","DOI":"10.1200\/JCO.18.01977","article-title":"Treatment and long-term clinical outcomes of incidental pulmonary embolism in patients with cancer: an international prospective cohort study","volume":"37","author":"Kraaijpoel","year":"2019","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.resmer.2023.101069_bib0023","doi-asserted-by":"crossref","first-page":"71\u201180","DOI":"10.1111\/jth.12071","article-title":"International clinical practice guidelines for the treatment and prophylaxis of thrombosis associated with central venous catheters in patients with cancer","volume":"11","author":"Debourdeau","year":"2013","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.resmer.2023.101069_bib0024","doi-asserted-by":"crossref","first-page":"411\u201121","DOI":"10.1111\/jth.14662","article-title":"Apixaban and dalteparin in active malignancy-associated venous thromboembolism: the ADAM VTE trial","volume":"18","author":"McBane","year":"2020","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.resmer.2023.101069_bib0025","doi-asserted-by":"crossref","first-page":"5546\u201153","DOI":"10.1182\/bloodadvances.2021005966","article-title":"Anticoagulation in cancer-associated thromboembolism with thrombocytopenia: a prospective, multicenter cohort study","volume":"5","author":"Carney","year":"2021","journal-title":"Blood Adv"},{"key":"10.1016\/j.resmer.2023.101069_bib0026","doi-asserted-by":"crossref","first-page":"1246\u20119","DOI":"10.1111\/jth.14015","article-title":"Management of cancer-associated thrombosis in patients with thrombocytopenia: guidance from the SSC of the ISTH","volume":"16","author":"Samuelson Bannow","year":"2018","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.resmer.2023.101069_bib0027","doi-asserted-by":"crossref","first-page":"468\u201173","DOI":"10.1634\/theoncologist.2017-0274","article-title":"Therapeutic Anticoagulation in patients with primary brain tumors or secondary brain metastasis","volume":"23","author":"Lin","year":"2018","journal-title":"Oncologist"},{"key":"10.1016\/j.resmer.2023.101069_bib0028","doi-asserted-by":"crossref","first-page":"e01638","DOI":"10.1002\/brb3.1638","article-title":"Risk of intracranial bleeding in patients with primary brain cancer receiving therapeutic anticoagulation for venous thromboembolism: a meta-analysis","volume":"10","author":"Porfidia","year":"2020","journal-title":"Brain Behav"},{"key":"10.1016\/j.resmer.2023.101069_bib0029","first-page":"1736\u201140","article-title":"A meta-analysis of intracranial hemorrhage in patients with brain tumors receiving therapeutic anticoagulation","volume":"14","author":"Zwicker","year":"2016","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.resmer.2023.101069_bib0030","doi-asserted-by":"crossref","first-page":"655\u201161","DOI":"10.1136\/jnnp-2020-324488","article-title":"Intracerebral haemorrhage in patients with brain metastases receiving therapeutic anticoagulation","volume":"92","author":"Wood","year":"2021","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"10.1016\/j.resmer.2023.101069_bib0031","doi-asserted-by":"crossref","first-page":"72\u20116","DOI":"10.1111\/jth.14336","article-title":"Intracranial hemorrhage with direct oral anticoagulants in patients with brain tumors","volume":"17","author":"Carney","year":"2019","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.resmer.2023.101069_bib0032","doi-asserted-by":"crossref","first-page":"6291\u20117","DOI":"10.1182\/bloodadvances.2020003238","article-title":"Intracranial hemorrhage with direct oral anticoagulants in patients with brain metastases","volume":"4","author":"Leader","year":"2020","journal-title":"Blood Adv"},{"key":"10.1016\/j.resmer.2023.101069_bib0033","doi-asserted-by":"crossref","first-page":"427\u201132","DOI":"10.1002\/onco.13698","article-title":"Safety of direct oral anticoagulants in central nervous system malignancies","volume":"26","author":"Swartz","year":"2021","journal-title":"Oncologist"},{"key":"10.1016\/j.resmer.2023.101069_bib0034","doi-asserted-by":"crossref","first-page":"781\u201190","DOI":"10.1016\/j.chest.2021.09.037","article-title":"Rivaroxaban vs dalteparin in cancer-associated thromboembolism: a randomized trial","volume":"161","author":"Planquette","year":"2022","journal-title":"Chest"},{"key":"10.1016\/j.resmer.2023.101069_bib0035","doi-asserted-by":"crossref","first-page":"1937","DOI":"10.3390\/cancers14081937","article-title":"In search of the appropriate anticoagulant-associated bleeding risk assessment model for cancer-associated thrombosis patients","volume":"14","author":"Po\u00e9nou","year":"2022","journal-title":"Cancers"},{"key":"10.1016\/j.resmer.2023.101069_bib0036","doi-asserted-by":"crossref","first-page":"359\u201173","DOI":"10.2147\/VHRM.S331614","article-title":"Factor XI inhibition for the prevention of venous thromboembolism: an update on current evidence and future perspectives","volume":"18","author":"Poenou","year":"2022","journal-title":"Vasc Health Risk Manag"},{"key":"10.1016\/j.resmer.2023.101069_bib0037","doi-asserted-by":"crossref","first-page":"291\u20118","DOI":"10.1182\/blood-2018-08-835595","article-title":"How I treat cancer-associated venous thromboembolism","volume":"133","author":"Kraaijpoel","year":"2019","journal-title":"Blood"},{"key":"10.1016\/j.resmer.2023.101069_bib0038","first-page":"371\u201181","article-title":"Effects of concomitant administration of anticancer agents and apixaban or dalteparin on recurrence and bleeding in patients with cancer-associated venous thromboembolism","volume":"148","author":"Verso","year":"2021","journal-title":"Eur J Cancer Oxf Engl"}],"container-title":["Respiratory Medicine and Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2590041223000818?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2590041223000818?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2023,12,23]],"date-time":"2023-12-23T09:20:18Z","timestamp":1703323218000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2590041223000818"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,6]]},"references-count":38,"alternative-id":["S2590041223000818"],"URL":"https:\/\/doi.org\/10.1016\/j.resmer.2023.101069","relation":{},"ISSN":["2590-0412"],"issn-type":[{"value":"2590-0412","type":"print"}],"subject":[],"published":{"date-parts":[[2024,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Cancer-associated thrombosis: How many patients seen in clinical practice would be eligible for a direct oral anticoagulant randomized controlled trial?","name":"articletitle","label":"Article Title"},{"value":"Respiratory Medicine and Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.resmer.2023.101069","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 SPLF and Elsevier Masson SAS. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"101069"}}